Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH

Stephen A Harrison, Mustafa Bashir, Sam E Moussa, Kevin McCarty, Juan Pablo Frias, Rebecca Taub, Naim Alkhouri, Stephen A Harrison, Mustafa Bashir, Sam E Moussa, Kevin McCarty, Juan Pablo Frias, Rebecca Taub, Naim Alkhouri

Abstract

Resmetirom (MGL-3196), a selective thyroid hormone receptor-β agonist, was evaluated in a 36-week paired liver biopsy study (NCT02912260) in adults with biopsy-confirmed nonalcoholic steatohepatitis (NASH). The primary endpoint was relative liver fat reduction as assessed by MRI-proton density fat fraction (MRI-PDFF), and secondary endpoints included histopathology. Subsequently, a 36-week active treatment open-label extension (OLE) study was conducted in 31 consenting patients (including 14 former placebo patients) with persistently mild to markedly elevated liver enzymes at the end of the main study. In patients treated with resmetirom (80 or 100 mg orally per day), MRI-PDFF reduction at OLE week 36 was -11.1% (1.5%) mean reduction (standard error [SE]; P < 0.0001) and -52.3% (4.4%) mean relative reduction, P < 0.0001. Low-density lipoprotein (LDL) cholesterol (-26.1% [4.5%], P < 0.0001), apolipoprotein B (-23.8% [3.0%], P < 0.0001), and triglycerides (-19.6% [5.4%], P = 0.0012; -46.1 [14.5] mg/dL, P = 0.0031) were reduced from baseline. Markers of fibrosis were reduced, including liver stiffness assessed by transient elastography (-2.1 [0.8] mean kilopascals [SE], P = 0.015) and N-terminal type III collagen pro-peptide (PRO-C3) (-9.8 [2.3] ng/mL, P = 0.0004 (baseline ≥ 10 ng/mL). In the main and OLE studies, PRO-C3/C3M (matrix metalloproteinase-degraded C3), a marker of net fibrosis formation, was reduced in resmetirom-treated patients (-0.76 [-1.27, -0.24], P = 0.0044 and -0.68, P < 0.0001, respectively). Resmetirom was well tolerated, with few, nonserious adverse events. Conclusion: The results of this 36-week OLE study support the efficacy and safety of resmetirom at daily doses of 80 mg and 100 mg, used in the ongoing phase 3 NASH study, MAESTRO-NASH (NCT03900429). The OLE study demonstrates a potential for noninvasive assessments to monitor the response to resmetirom from an individual patient with NASH.

© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.

Figures

Fig. 1
Fig. 1
Disposition (A) of and treatment schematic (B) of patients in the MGL‐3196‐05 main and OLE studies. Abbreviations: BL, baseline; DC, discontinued.
Fig. 2
Fig. 2
MRI‐PDFF results in the OLE study relative median (−54.6 [−35.6, −65.8]) (A) and absolute mean fat reduction (B) (Table 2) as determined by MRI‐PDFF at week 36 in the primary population (Pbo/Res and Res/Res patients with a dose increase during the OLE study) and by final dose. Time course of PDFF in the Pbo/Res (blue line) and primary Res/Res (red line) population compared with change in PRO‐C3.
Fig. 3
Fig. 3
Time course in OLE study patients of liver enzymes ALT, AST, and GGT (A) and SHBG (B). The baseline (week 0) is the OLE baseline for both Res/Res and Pbo/Res patients.
Fig. 4
Fig. 4
Time course of PRO‐C3/C3M in the main (A) and OLE (B) studies. Both the main and OLE times are shown in (B). Res/Res patients were on resmetirom for both the main and OLE 36‐week studies, and Pbo/Res were on placebo during the main study and started on resmetirom on OLE day 1 for 36 weeks.
Fig. 5
Fig. 5
Time course of CT1 and PDFF and dose in individual Pbo/Res and Res/Res patients. (A) CT1 images at indicated assessment times of a Pbo/Res patient. (B,C) The Res/Res and Pbo/Res patient, respectively, time course of CT1, PDFF, and dose administered over time from the start of the main study to the end of the OLE.
Fig. 6
Fig. 6
Effects of resmetirom on RT3 and FT3/RT3 in patients with NASH. (A) Baseline FT3/RT3 in normal (non‐NASH) and NASH according to liver biopsy fibrosis stage. Shown as a box and whisker plot with box defined by quartile 1, 3, and median, with quartile line shown; “x” indicates the mean, SD, and error bars. (B) Effect of resmetirom on thyroid pathway hormones at week 36 in the main study or OLE. Compared with placebo in the main study, within‐group comparison over time in the OLE. Abbreviation: F2/F3, patients with baseline NASH fibrosis stage of F2 or F3.

References

    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328‐357.
    1. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063‐2072.
    1. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state‐of‐the‐art review. J Am Coll Cardiol 2019;73:948‐963.
    1. Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non‐alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:728‐736.
    1. Angulo P, Kleiner DE, Dam‐Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389‐397.e310.
    1. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis. Hepatology 2017;65:1557‐1565.
    1. Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells 2020;9:1005.
    1. Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, et al. Performance of the PRO‐C3 collagen neo‐epitope biomarker in non‐alcoholic fatty liver disease. JHEP Rep 2019;1:188‐198.
    1. Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol 2018;68:362‐375.
    1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11‐20.
    1. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non‐alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo‐controlled phase 3 trial. Lancet 2019;394:2184‐2196.
    1. Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 2020;73:26‐39.
    1. Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, et al. Insulin sensitizer MSDC‐0602K in non‐alcoholic steatohepatitis: a randomized, double‐blind, placebo‐controlled phase IIb study. J Hepatol 2020;72:613‐626.
    1. Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, et al. A randomized, placebo‐controlled trial of emricasan in patients with NASH and F1–F3 fibrosis. J Hepatol 2020;72:816‐827.
    1. Sinha RA, Bruinstroop E, Singh BK, Yen PM. Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid 2019;29:1173‐1191.
    1. Bohinc BN, Michelotti G, Xie G, Pang H, Suzuki A, Guy CD, et al. Repair‐related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. Endocrinology 2014;155:4591‐4601.
    1. Kelly MJ, Pietranico‐Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, et al. Discovery of 2‐[3,5‐dichloro‐4‐(5‐isopropyl‐6‐oxo‐1,6‐dihydropyridazin‐3‐yloxy)phenyl]‐3,5‐dio xo‐2,3,4,5‐tetrahydro[1,2,4]triazine‐6‐carbonitrile (MGL‐3196), a highly selective thyroid hormone receptor beta agonist in clinical trials for the treatment of dyslipidemia. J Med Chem 2014;57:3912‐3923.
    1. Taub R, Chiang E, Chabot‐Blanchet M, Kelly MJ, Reeves RA, Guertin MC, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL‐3196, a liver‐targeted thyroid hormone receptor‐beta agonist. Atherosclerosis 2013;230:373‐380.
    1. Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL‐3196) for the treatment of non‐alcoholic steatohepatitis: a multicentre, randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet 2019;394:2012‐2024.
    1. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme‐linked immunosorbent assay (ELISA) for a MMP‐9 proteolytically revealed neo‐epitope of type III collagen. Clin Biochem 2010;43:899‐904.
    1. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717‐1730.
    1. Park PH, Sanz‐Garcia C, Nagy LE. Adiponectin as an anti‐fibrotic and anti‐inflammatory adipokine in the liver. Curr Pathobiol Rep 2015;3:243‐252.
    1. Hashemi SA, Alavian SM, Gholami‐Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non‐alcoholic fatty liver disease: a systematic review and meta‐analysis. Caspian J Intern Med 2016;7:242‐252.
    1. Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2016;9:692‐701.
    1. Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI‐PDFF as an endpoint in NASH trials. Hepatology 2018;68:763‐772.
    1. Kim D, Vazquez‐Montesino LM, Escober JA, Fernandes CT, Cholankeril G, Loomba R, et al. Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all‐cause and cardiovascular mortality. Am J Gastroenterol 2020;115:1496‐1504.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever